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ABSTRACT
OBJECTIVE: To analyze the cost-effectiveness of treatment regimens with 
cyclosporine or tacrolimus, five years after renal transplantation.
METHODS: This cost-effectiveness analysis was based on historical cohort 
data obtained between 2000 and 2004 and involved 2,022 patients treated 
with cyclosporine or tacrolimus, matched 1:1 for gender, age, and type and 
year of transplantation. Graft survival and the direct costs of medical care 
obtained from the National Health System (SUS) databases were used as 
outcome results.
RESULTS: Most of the patients were women, with a mean age of 
36.6 years. The most frequent diagnosis of chronic renal failure was 
glomerulonephritis/nephritis (27.7%). In five years, the tacrolimus group 
had an average life expectancy gain of 3.96 years at an annual cost of 
R$78,360.57 compared with the cyclosporine group with a gain of 4.05 
years and an annual cost of R$61,350.44.
CONCLUSIONS: After matching, the study indicated better survival 
of patients treated with regimens using tacrolimus. However, regimens 
containing cyclosporine were more cost-effective.
DESCRIPTORS: Immunosuppressive Agents, therapeutic use. Kidney 
Transplantation, economics. Graft Survival. Transplantation Tolerance, 
drug effects. Cost-Benefit Analysis. Unified Health System. Cohort Studies.
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Renal disease is mainly caused by diabetes mellitus and 
arterial hypertension and can be defined as an injury 
arising from multiple causes, leading to a progressive 
loss of renal function.5 In the disease’s final stage, the 
available renal replacement therapies are hemodialysis, 
peritoneal dialysis, and renal transplantation.5 Kidney 
transplantation is recognized as the preferred approach 
for chronic kidney disease treatment, from both clinical 
and economical perspectives. Technological advances 
in immunosuppressive therapy have contributed 
significantly to the consideration of kidney transplan-
tation as the best option for chronic kidney disease. 
The main goal of such therapy is to prolong graft 
survival by preventing acute and chronic rejection of 
the transplanted organ.7 Chronic rejection represents 
20.0%-70.0% of graft losses after the first year of trans-
plantation, and the risk factors of chronic rejection are 
failure of the immunosuppressive regimen used and 
the presence and intensity of acute rejection episodes.a
Clinical immunosuppression began in the early 1950s 
with the use of glucocorticoids combined with azathi-
oprine and/or anti-lymphocyte globulins. In the early 
RESUMO
OBJETIVO: Analisar custo-efetividade de regimes terapêuticos com 
ciclosporina ou tacrolimo cinco anos após transplante renal.
MÉTODOS: Análise de custo-efetividade com base em dados de coorte histórica 
2000-2004, com 2.022 pacientes tratados com ciclosporina ou tacrolimo e 
pareados 1:1 segundo sexo, idade, tipo e ano de transplante. A sobrevida do 
enxerto e os custos diretos de cuidados médicos a partir das bases de dados do 
Sistema Único de Saúde foram utilizados como medida de resultado.
RESULTADOS: A maioria dos pacientes era do sexo feminino e média de idade 
de 36,6 anos. O diagnóstico mais frequente de insuficiência renal crônica foi 
a glomerulonefrite/nefrite (27,7%). Em cinco anos, o grupo tacrolimo obteve 
uma expectativa de vida média de 3,96 anos de vida ganhos ao custo anual de 
R$78.360,57 ante 4,05 anos de vida ganhos e de R$61.350,44 para ciclosporina.
CONCLUSÕES: Após o pareamento, o estudo não mostrou melhor sobrevida 
dos pacientes com regimes que usam tacrolimo. Além disso, regimes contendo 
ciclosporina foram mais custo-efetivos.
DESCRITORES: Imunossupressores, uso terapêutico. Transplante de 
Rim, economia. Sobrevivência de Enxerto. Tolerância ao Transplante, 
efeitos de drogas. Análise Custo-Benefício. Sistema Único de Saúde. 
Estudos de Coortes.
INTRODUCTION
1980s, cyclosporine was introduced into the market 
and represented a significant gain in renal allograft 
survival. Cyclosporine, which is extracted from the 
Tolypocladium inflatum cytoplasmic fungus, inac-
tivates calcineurin and prevents interleukin (IL)-2 
gene transcription. Cyclosporine may lead to adverse 
events such as nephrotoxicity, chronic hemolytic 
uremic syndrome, hyperlipidemia, hypertension, 
gingival hyperplasia, diabetes mellitus, and tremors.1,b 
Tacrolimus, a polycyclic macrolide, emerged in the 
early 1990s as a therapeutic alternative to cyclospo-
rine. Due to its higher affinity for calcineurin, it has 
been presented to the market as more potent than 
cyclosporine. Similar to cyclosporine, tacrolimus can 
cause nephrotoxicity and hemolytic uremic syndrome, 
but causes fewer episodes of hyperlipidemia, hyper-
tension, and cosmetic effects.1,16 Nevertheless, it is 
associated with a higher incidence of diabetes mellitus 
after transplantation.22 Since 1999, other drugs have 
been increasingly become available, such as sirolimus, 
a macrolide with a structure similar to that of tacro-
limus, and more recently, everolimus.1
a Sociedade Brasileira de Nefrologia. Diretrizes em transplante renal. São Paulo; 2006 [cited 2008 Jun 13]. Available from: 
http://www.sbn.org.br/diretrizes
b Ministério da Saúde, Secretaria de Atenção à Saúde. Portaria SAS/MS 221 de 2 de abril de 2002. Aprova o protocolo clínico e diretrizes 
terapêuticas de medicamentos excepcionais e de alto custo no SUS. Diario Oficial Uniao [Internet]. abr 2002 [cited 2008 Jul 29] sessão 1. 
Pg. 59. Available from: http://dtr2001.saude.gov.br/sas/PORTARIAS/PORT2002/PT-221.htm
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Worldwide, Brazil is the second in the number of trans-
plants performed annually, after only the United States. 
Most transplantations in Brazil are performed as per 
the Brazilian Unified Health System (SUS), which in 
2013 allowed 4,671 kidney transplants, corresponding 
to a cost of approximately 100 million dollars.c Actions 
to improve the care of patients with renal disease 
include the publication of the Clinical Protocols and 
Therapeutic Guidelinesb in 2002 to ensure compre-
hensive pharmaceutical assistance for the high-cost 
drugs used in kidney transplantation. Also, in 2004, a 
National Care Policy for Persons with Renal Disease 
targeted specific actions in renal replacement therapies.d
The Clinical Protocol and Therapeutic Guidelines 
for kidney transplantation recommend maintaining 
immunosuppression regimens after transplantation 
with cyclosporine and concomitant use of azathio-
prine and corticosteroids. Alternatively, cyclosporine 
can be replaced by tacrolimus, and azathioprine can 
be replaced by mycophenolate mofetil or rapamycin.b 
Despite the rising economic impact of the distribution 
of these drugs by SUS, the effects on long-term graft 
and patient survival remain unknown. Thus, the aim 
of the present study was to analyze the cost-effective-
ness of maintenance immunosuppressive regimens 
with tacrolimus versus those with cyclosporine over a 
5-year follow-up period.
METHODS
We conducted a cost effectiveness analysis using data 
from a cohort study conducted from January 2000 to 
December 2004. The study included patients under-
going kidney transplantation who used immunosup-
pressive regimens containing tacrolimus or cyclospo-
rine in all SUS transplant centers in Brazil. Patients 
were identified in the SUS national hospital ambula-
tory and mortality databases by probabilistic record 
linkage of administrative data.3 The linkage allowed 
the (re)construction of the trajectory of patients on a 
large scale, and the matching of records from these 
databases reached 97.3% agreement between two cler-
ical reviewers.21
We evaluated the time-to-failure of immunosuppressive 
therapy, i.e., graft loss, as death or the resumption of 
dialysis for more than three months without concomi-
tant use of immunosuppressive drugs. The last recorded 
date of immunosuppressive drug dispensation or death 
was considered the event date. Censoring was charac-
terized as loss of follow-up or study completion.
Entry into the cohort was defined as the transplantation date 
registered at the SUS hospital database. We considered the 
immunosuppressive regimens containing tacrolimus or 
cyclosporine, even when combined with other immunosup-
pressive drugs registered at the SUS ambulatory database. 
We included only incident patients who underwent trans-
plantation between January 2000 and December 2003 and 
were followed-up for at least 12 months.
We excluded patients who survived less than six months 
post-transplantation and those who switched from 
cyclosporine to tacrolimus-based regimens, or vice 
versa. Then we matched 1:1 patients in each group by 
the following variables: type of transplantation (living 
or deceased donor), sex (male or female), age in years 
at the time of transplantation, and year of transplanta-
tion (2000, 2001, 2002, or 2003). When more than one 
patient in either group was a therapeutic candidate for 
pairing by the four variables, the pair allocation was 
randomly selected.
We used the Kaplan-Meier method to estimate the 
cumulative survival probability. A significance level 
of 5% was considered, and statistical analysis was 
conducted with R software version 2.5.0 (R Foundation 
for Statistical Computing). The economic analysis 
adopted the public financing perspective and was 
limited to direct health care costs. To assess individual 
costs, we identified all procedures, and their costs were 
based on the SUS hospital and ambulatory databases 
for each patient considering the month as unit of time. 
From these data, we calculated the amount spent (in 
Brazilian Real – BRL) per patient, according to the 
following categories: hospitalization, dialysis, clinical 
patient monitoring, and drugs supplied (cyclosporine, 
tacrolimus, other immunosuppressive agents, and other 
drugs). Thus, we calculated the total expenditure of 
each group of patients and the average cost per patient 
(standard deviation) for the period.
Further details of the methodological procedures are 
described in our previous publication.9 We updated the 
values until December 2012 based on the Consumer 
Price Index (Índice de Preços ao Consumidor Amplo).e
We developed a Markov model using the TreeAge 
Pro® 2009 program, with the primary focus on a 5-year 
cost effectiveness analysis to compare the use of tacro-
limus versus cyclosporine regimens in preventing graft 
c Ministério da Saúde, Secretaria de Gestão Estratégica e Participativa, Departamento de Informática do SUS - DATASUS. Brasília (DF); 
2014 [cited 2014 Oct 3]. Sistema de Internações Hospitalares do SUS. Available from: http://www2.datasus.gov.br/DATASUS/index.
php?area=0202&VObj=http://tabnet.datasus.gov.br/cgi/deftohtm.exe?sih/cnv/qi
d Associação Brasileira de Transplante de Órgãos - ABTO. Dimensionamento dos transplantes no Brasil e em cada estado (2006-2013). Regist 
Bras Transplantes [Internet]. 2013 [cited 2014 Jul 27];19(4):3-79. Available from: http://www.abto.org.br/abtov03/Upload/file/RBT/2013/
rbt2013-parcial%281%29.pdf
e Instituto Brasileiro de Geografia e Estatística. Índice de Preços ao consumidor. Rio de Janeiro; 2012 [cited 2014 Nov 24]. Available from: 
http://www.ibge.gov.br/home/estatistica/indicadores/precos/inpc_ipca/ipca-inpc_201204_1.shtm
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rejection in kidney transplantation. Cyclosporine was 
selected as the comparative treatment in the model 
because it is the first choice immunosuppressant in 
SUS clinical protocols.b
Survival by follow-up year and costs were calculated 
directly from the historical cohort. The model consisted 
of two health states: alive with transplant (initial health 
state) and treatment failure (graft loss and/or death). 
A discount rate of 5.0% per year was adopted for the 
costs and results.
The Markov model was used to estimate clinical benefits 
in life-years gained (LYG) with a functioning graft and 
the costs of alternative drugs in the follow-up period. 
We compared the treatment alternatives according to 
the incremental cost effectiveness ratio according to 
the cost effectiveness threshold suggested by the World 
Health Organization:f 1-3× the gross domestic product 
per capita (21,252.00 BRL to 63,756.00 BRL; refer-
ence year, 2011) per life-year adjusted for disability 
prevented. Because life-years adjusted for disability 
were estimated, the LYG was considered proxy.
Sensitivity analysis was performed to determine the 
impact on the estimated incremental cost effectiveness 
ratio. Unidirectional analysis was conducted by varying 
the individual values: discount rates (0.0%, 5.0%, and 
10.0%), costs, magnitude of treatment effectiveness, 
and graft survival (minimum and maximum values of 
the transition probabilities).
This study is part of the Pharmacoeconomics and 
Pharmacoepidemiological Evaluation of High-Cost 
Drugs in Brazil project (Avaliação farmacoeconômica 
e epidemiológica do Programa de Medicamentos 
Excepcionais do SUS no Brasil, 2000-2005), which 
was approved by the Ethics Committee of Universidade 
Federal de Minas Gerais (397/2004 and 0101/2006).
RESULTS
Among 9,298 kidney transplantations, we identified 
8,981 different patients. Only 11.0% of them were 
not registered as drug users in the ambulatorial SUS 
system. From January 2000 to December 2004, among 
the various combinations of drugs supplied by SUS, we 
observed that 4,392 (49.0%) patients were exclusively 
on immunosuppressive regimens based on cyclospo-
rine and 1,294 (14.0%) patients were exclusively on 
tacrolimus regimens. Then, we established 1,011 pairs 
matched by type of transplantation, gender, age, and 
year of transplantation between the cyclosporine and 
tacrolimus groups.
Table 1 shows the final distribution of the kidney 
transplantation patients and their immunosuppres-
sive regimens. Of the 2,022 individuals included in 
the cohort, the majority (50.4%) were female, and the 
mean age at transplantation was 36.6 years. The most 
frequent primary causes of chronic kidney disease were 
glomerulonephritis, interstitial nephritis, pyelonephritis 
(27.7%), hypertension, cardiovascular disease (20.4%), 
organ and tissue transplantation failure or rejection 
(6.3%), diabetes (3.6%), cystic kidney disease (2.0%), 
and other causes and undetermined diagnoses (38.0%). 
The large number of patients with undetermined diag-
noses may be related to the advanced clinical stage of 
renal disease in many patients, which complicates the 
establishment of the disease’s etiology. Transplantation 
was performed with living donors most often (62.7%). 
Immunosuppressive treatment failure occurred 
in 9.7% of the patients (death in 5.9% and graft loss 
in 3.8%). Table 2 presents the annual probabilities of 
graft survival in the period of 1-5 years observed for 
each group.
Regarding economic assessment, we observed signifi-
cantly higher spending in the tacrolimus-based regimen 
group for the following categories of resources: study 
drug [10.1 million for cyclosporine and 26.9 million for 
tacrolimus (BRL)], hospitalization [38.5 million for cyclo-
sporine and 40.2 million for tacrolimus (BRL)] (Table 3).
In five years, tacrolimus treatment resulted in an 
average life expectancy of 3.96 LYG compared with 
4.05 LYG in case of cyclosporine, considering a 5.0% 
discount on the costs and effects. The annual cost of 
treatment was BRL 78,360.57 with tacrolimus and BRL 
61,350.44 with cyclosporine. Based on these results, 
we observed that tacrolimus treatment was more costly 
and less effective (Table 4).
For the sensitivity analysis, different discount rates 
(0.0%, 10.0%, and 5.0%) and the minimum and 
maximum prices of the medication alternatives also 
were applied to determine the extension at which 
the arbitrary selection of the rate affected the study 
conclusions. In five years, tacrolimus treatment 
resulted in an expected median graft survival of 
4.31 LYG compared with 4.42 LYG obtained with 
cyclosporine. The annual cost of treatment was BRL 
80,061.50 with tacrolimus and BRL 62,453.42 with 
cyclosporine. Applying a 10.0% discount to the costs 
and effects, we obtained an average of 3.66 LYG with 
tacrolimus and 3.74 LYG with cyclosporine. The 
annual cost of treatment was then BRL 76,914.22 
with tacrolimus and BRL 60,410.53 with cyclospo-
rine. In both scenarios, cyclosporine treatment was 
associated with less cost and greater effectiveness 
compared with tacrolimus treatment.
f World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE): cost-effectiveness thresholds. Geneva; 2005 [cited 
2014 Nov 24]. Available from: http://www.who.int/choice/costs/CER_thresholds/en
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We also applied a 5.0% discount rate to costs and effects 
and varied the magnitude of treatment effectiveness in the 
case of graft survival (transition probability minimum and 
maximum values) to determine the impact on the incre-
mental cost effectiveness ratio estimate. For the maximum 
values, tacrolimus resulted in an expected median survival 
of 4.09 LYG, which was less than 4.20 LYG achieved 
with cyclosporine. The annual cost of treatment was 
BRL 78,982.95 with tacrolimus and BRL 61,718.68 
with cyclosporine. Thus, tacrolimus treatment was more 
costly and less effective than cyclosporine treatment. For 
the minimum values, tacrolimus resulted in an expected 
median survival of 3.83 LYG and cyclosporine resulted 
in that of 3.95 LYG. The annual cost of treatment was 
BRL 77,870.27 with tacrolimus and BRL 61,053.77 for 
cyclosporine. Again, tacrolimus treatment was more costly 
and less effective than cyclosporine treatment.
DISCUSSION
In this study with matched groups, no evidence was 
found of a therapeutic advantage of tacrolimus over 
cyclosporine in kidney transplantation. Our findings 
were consistent with a previous review comparing the 
effects of these two drugs as primary therapy for kidney 
transplantation that showed significantly reduced graft 
failure and death in recipients treated with tacrolimus 
versus those treated with cyclosporine at six months 
and at three years after transplantation. However, in 
this review, a significant difference was not observed 
at one, two, four and five years after transplantation.25
A recent retrospective analysis of 51,303 patients 
reported that after five years, graft survival in recipients 
of kidney transplants from cadaveric donors was equiv-
alent in patients receiving immunosuppressive regi-
mens based on cyclosporine or tacrolimus. The same 
study discussed the selection of tacrolimus, because 
it is most commonly prescribed for patients who are 
generally considered at high risk for graft failure. The 
analysis performed across four well-defined risk groups 
of patients showed no significant differences in survival 
between those treated with tacrolimus and those 
treated with cyclosporine in presensitized recipients, 
Table 1. Distribution of kidney transplantation patients receiving immunosuppressive regimens containing cyclosporine or 
tacrolimus in a matched cohort. Brazil, 2000-2004.
Cyclosporine Tacrolimus 
 
Regimen Combination n Regimen Combination n
Cyclosporine 
(monotherapy)
316 Tacrolimus 
(monotherapy)
146
Cyclosporine + 
Azathioprine
229 Tacrolimus + 
Azathioprine
231
+ Mycophenolate 69 + Mycophenolate 53
+ Mycophenolate/
Sirolimus
9 + Mycophenolate/
Sirolimus
3
+ Sirolimus 4 + Sirolimus 1
Cyclosporine + 
Mycophenolate
335 Tacrolimus + 
Mycophenolate
478
+Sirolimus 31 +Sirolimus 35
+ Azathioprine 5 + Azathioprine 36
Cyclosporine + Sirolimus 13 Tacrolimus + Sirolimus 28
Total 1,011 Total 1,011
Table 2. Annual probability of graft survival (95% confidence interval) of kidney transplantation patients, according to the 
therapeutic regimen in a matched cohort. Brazil, 2000-2004.
Cyclosporine Tacrolimus
 
Follow-up Graft survival probability 95%CI Graft survival probability 95%CI
1st year 0.975 0.970;0.988 0.967 0.963;0.983 
2nd year 0.935 0.922;0.954 0.924 0.909;0.944 
3rd year 0.892 0.872;0.919 0.870 0.851;0.901 
4th year 0.850 0.838;0.898 0.870 0.783;0.860
5th year 0.820 0.762;0.882 0.790 0.741;0.849
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retransplanted patients, diabetes patients, and recipients 
of grafts from donors aged 65 years or older.17
In addition to being considered more appropriate for 
liver transplantation than kidney transplantation, tacro-
limus is associated with the side effect of diabetes 
development.13,15,17,25 Tacrolimus and micophenolate 
maintenance therapy is also one of the most important 
risk factors for polyoma virus nephropathy develop-
ment, which is a common cause of kidney transplant 
failure.20 In Brazil, the most common maintenance 
regimen used includes cyclosporine, but an increasing 
number of patients have been treated with tacrolimus. 
This should not happen, according to clinical protocols 
in force in Brazil, because most kidney transplantations 
are performed from living donors, and nearly 80.0% 
are performed with organs donated by close relatives. 
In this situation, a better match between the donor and 
recipient is expected, and the general recommendation 
is to use tacrolimus when clinical conditions indicate a 
higher risk of graft rejection or toxicity to the patient.
In a cohort study of 5,686 patients, with unpaired 
groups, the treatment failure risk in patients receiving 
tacrolimus was considered to be 1.38 times higher than 
in those receiving cyclosporine, after adjusting the 
model for confounding factors.10 A lower survival with 
tacrolimus was also identified in a study of data from 
the United Network for Organ Sharing in the United 
States, which included more than 7,000 transplantation 
patients, and the risk related to tacrolimus was found 
to be increased by 1.28-fold.12
The widespread use of tacrolimus is usually based on 
the notion that the drug reduces acute rejection better in 
comparison with cyclosporine, which would generate 
graft survival benefits. However, studies with a large 
number of patients which were controlled for many 
confounders could not demonstrate differences in graft 
survival at five years between patients who received 
tacrolimus and those who received cyclosporine regi-
mens.12,17,25 Likewise, the data did not show an advan-
tage in graft survival in the long term with tacrolimus. 
It should be noted that the five-year follow-up period 
for the cohort was sufficient to observe the event, even 
though the length of graft and patient survival reported in 
the literature was approximately 10 years. An economic 
evaluation focusing on immunosuppressive regimens 
used in kidney transplantation in Germany found a 
small difference in graft survival favoring tacrolimus in 
a period of 10 years, but due to its considerably higher 
cost, it was not considered a cost effective alternative.11
The assessment of incremental cost effectiveness for 
the five-year period showed economic dominance of 
regimens based on cyclosporine over those based on 
tacrolimus. We highlight the occurrence of major hospi-
talization expenses and medications for the tacrolimus 
group during the period. Higher spending on medicines Ta
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was already expected, as once monthly tacrolimus 
treatment was 2.6 times more expensive than that with 
cyclosporine, but it was hoped that other expenses, 
primarily related to hospitalization, would be lower, 
which could afford a positive incremental value with 
regimens based on tacrolimus.
The variables identified as risk factors for clinical and 
surgical kidney transplantation were as follows: age less 
than five years or greater than 50 years and systemic 
diseases [diabetes mellitus, amyloidosis, Fabry disease, 
scleroderma, previous gastrointestinal disease (peptic 
ulcer, pancreatitis, liver disease, diverticulosis, morbid 
obesity, and malnutrition), previous malignancy, 
previous transplantations, and others].1 In a previous 
publication focusing on this cohort, both age and the 
presence of diabetes were associated with a high risk 
of treatment failure, which impacted patient survival.10 
Hypertension and heart disease did not appear as risk 
factors in the final model. One explanation is that these 
conditions are associated more with the baseline diag-
nosis, and these patients are better able to control their 
disease after transplantation, considering the focus that 
SUS has given to them. However, this interpretation 
requires confirmation in more specific studies.
The literature indicates that diabetes, hypertension, and 
glomerulonephritis, in descending order, are the main 
primary diagnoses that lead to chronic kidney disease 
among patients undergoing dialysis.4 The present study 
identified these diagnoses, but in a different order. One 
hypothesis for this difference is that nephritis does not 
represent a chronic condition, and thus, these patients 
would be more likely to be eligible for kidney trans-
plantation than those with hypertension and diabetes. 
Another aspect to be considered is the high prevalence 
of other undetermined causes and diagnoses observed in 
this administrative database. A review showed that the 
influence of sociocultural and socioeconomic dispari-
ties on kidney transplantation outcomes remains largely 
unclear and identified a need for more research to better 
understand the factors that contribute to these dispari-
ties and their mechanisms.8
In addition, a variety of factors influence graft survival 
in the short and long term, including the following: the 
combination of antigens between the donor and recip-
ient with respect to histocompatibility, ABO blood 
group, a higher level of panel reactive antibodies, race, 
gender, ages of donor and recipient, ischemic time for 
donor organ, organ size compatibility, acute rejection 
crises, postoperative acute tubular necrosis, time of dial-
ysis, and history of previous transplantations. Besides 
these, induction therapy with a lymphocyte depletion 
agent or an interleukin-2 receptor antagonist can effec-
tively protect against rejection in the first crucial months 
after transplantation. However, there is no evidence of 
its benefits on graft survival in the long-term.1,2,7,16,22,b 
Information on most of these factors was not available 
for this study. However, we considered the evidence 
of an increased risk of rejection associated with sex, 
recipient age, and type of transplantation, to pair the 
patient groups.14 Also, in the SUS, kidney transplanta-
tions are performed with living and cadaveric donors.b
Despite the increased availability of immunosuppres-
sive drugs, the greatest benefit of such treatment seems 
to be reducing the number of episodes of acute rejec-
tion, which is one of the main risk factors for chronic 
allograft nephropathy.19 However, the effects on short- 
and long-term survival have been less substantiated 
despite the addition of new medicines, such as tacro-
limus, to the initial therapeutic regimen involving 
azathioprine and prednisone. Studies showed an initial 
increase in survival among transplantation patients 
who received a therapeutic regimen based on tacro-
limus, compared with those who received cyclospo-
rine-based regimens. Nevertheless, long-term studies 
did not uniformly confirm this apparent advantage of 
tacrolimus immunosuppression.12,14,19
Observational data are particularly likely to be affected 
by confounding factors in studies focusing on thera-
peutic effects, because the reasons why a physician or 
patient selects a particular treatment are also strongly 
linked to the health outcome.6 Another limitation of this 
study is related to the data collection method. We used 
data recorded in large administrative databases devel-
oped by the health system, which were collected retro-
spectively; these data may not be complete or may be 
of low quality.23 Moreover, information on a variety of 
factors that influence graft survival, such as ischemia 
time, histocompatibility, and time to dialysis, in the 
short and long term were not available in the database.
Regarding the use of health expenditures as a proxy for 
costs, in other studies, the cost and production functions 
are defined as expenditures executed by the financier 
Table 4. Results of cost-effectiveness (5.0% discount on the costs and effects) of treatment regimens with cyclosporine or 
tacrolimus after kidney transplantation. Brazil, 2000-2004.
Regimen Cost (BRL) Incremental cost 
(BRL)
Effectiveness 
(LYG)
Incremental 
effectiveness
CER 
(BRL/LYG)
ICER
Cyclosporine 61,350.44 4.05 15,146.56
Tacrolimus 78,360.57 17,010.13 3.96 -0.09 19,791.59 Dominated
LYG: life-years gained; CER: Cost effectiveness ratio; ICER: Incremental cost effectiveness ratio; BRL: Brazilian Real
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ERRATUM
No artigo: “Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil” publicado 
no periodico “Revista de Saúde Pública”, volume 49 de 2015, em Conclusions of the Abstract.
Where it reads:
“After matching, the study indicated better survival of patients treated with regimens using tacrolimus. However, 
regimens containing cyclosporine were more cost-effective.”
It should read:
“After matching, the study did not indicate better survival of patients treated with regimens using tacrolimus. 
Moreover, regimens containing cyclosporine were more cost-effective.”
